CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ (8,123)	$ 46,162
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	41,231	34,375
Impairment of intangible assets	15,963
Amortization of premium/discount on purchased securities	351	658
Write-down of inventory to net realizable value		278
Non-cash equity-based compensation expense	11,342	6,684
Amortization of debt discount and debt issuance costs	5,940	5,501
Change in fair value of contingent consideration	1,399	1,639
Deferred income taxes	(1,371)	23,643
Changes in operating assets and liabilities:
Accounts receivable, net	19,592	(17,849)
Inventories	281	(1,027)
Receivable from collaboration	428	(1,097)
Prepaid and other current assets	(273)	3,331
Accounts payable and accrued expenses	4,700	10,231
Deferred revenues	17,204	(44,376)
Other assets and liabilities	1,970	3,535
Net cash provided by operating activities	110,634	71,688
Cash flows from investing activities:
Acquisition of Lumara Health, net of acquired cash		562
Proceeds from sales or maturities of investments	42,500	6,464
Purchase of investments	(98,795)	(291,085)
Capital expenditures, net of proceeds from sale of assets	(2,587)	(677)
Net cash used in investing activities	(58,882)	(284,736)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discount and other expenses		188,864
Long-term debt principal payments	(8,752)	(16,686)
Payment of contingent consideration	(149)	(190)
Payments for repurchases of common stock	(20,000)
Proceeds from the exercise of stock options	809	11,648
Proceeds from the issuance of common stock under ESPP	760
Payments of employee tax withholding related to equity-based compensation	(2,015)
Net cash (used in) provided by financing activities	(29,347)	183,636
Net increase (decrease) in cash and cash equivalents	22,405	(29,412)
Cash and cash equivalents at beginning of the period	228,705	119,296
Cash and cash equivalents at end of the period	$ 251,110	$ 89,884